What Is a Compounding Pharmacy?

A compounding pharmacy creates custom medications for patients whose needs a standard commercial drug cannot meet — a child who needs a liquid instead of a pill, a patient with an allergy to a commercial dye, or someone prescribed a hormone combination that no manufacturer produces. The finished product has not been evaluated by the FDA for safety or effectiveness. This guide explains what that means for you, how compounding pharmacies are regulated, and what to check before you fill a prescription.

Key takeaways

• A compounding pharmacy creates custom medications for individual patients by combining, mixing, or altering drug ingredients — filling clinical gaps that commercial manufacturing cannot.
• Compounded drugs are not FDA-approved. The FDA reviews the ingredients used, not the finished compounded product.
• Two types exist: 503A pharmacies prepare patient-specific prescriptions under state oversight; 503B outsourcing facilities produce larger batches under direct FDA inspection and current Good Manufacturing Practice (cGMP) standards.
• Compounded prescriptions account for an estimated 1–3% of all US prescriptions, with hormone replacement therapy making up approximately 36% of compounded formulations (Alliance for Pharmacy Compounding, 2025–2026).
• Verifying a pharmacy means checking three things: a current state pharmacy board license, PCAB or NABP accreditation, and a certificate of analysis (COA) for each batch.

Before you start All compounded prescriptions — including peptides, hormones, and other specialized formulations — require a prescription from a licensed physician. The quality of any compounded medication depends entirely on the pharmacy’s sourcing, equipment, and practices, not on FDA review of the finished product. Ask for documentation before you fill.

What is a Compounding Pharmacy?

A compounding pharmacy is a licensed pharmacy where a pharmacist — or a physician under supervision — combines, mixes, or alters drug ingredients to create a medication tailored to one specific patient’s needs. The result is a compounded drug: a preparation that does not exist in that exact form, dose, or formulation from a commercial manufacturer.

The FDA defines pharmaceutical compounding as “the practice of a licensed pharmacist or physician combining, mixing, or altering ingredients of a drug to create a medication tailored to the needs of an individual patient.”

Compounding fills gaps that commercial manufacturing cannot. A child who cannot swallow a pill needs a flavored liquid. A patient allergic to a dye used in a standard capsule needs an allergen-free version. A hormone replacement patient needs a specific combination that is not commercially available. These are the clinical problems compounding exists to solve.

The most important thing to understand: compounded drugs are not FDA-approved. The FDA approves ingredients — bulk drug substances must meet FDA registration requirements and come from FDA-registered manufacturers. The FDA does not evaluate the finished compounded product for safety, effectiveness, or quality before it reaches you. That process — the full New Drug Application (NDA) review — applies to manufactured drugs, not to compounded preparations.

Approximately 7,500 pharmacies in the USA specialize in compounding (American Pharmacists Association, 2020). Over 32,000 of the approximately 56,000 US community pharmacies offer some form of compounding service, though most handle only basic, non-sterile preparations. Compounded prescriptions account for an estimated 1–3% of all US prescriptions (Alliance for Pharmacy Compounding, 2025–2026 Snapshot).

Learn more about how compounding pharmacies are regulated at the federal and state level.

503A vs. 503B: The Two Types of Compounding Pharmacies

The Drug Quality and Security Act (DQSA) of 2013 created the current two-track regulatory framework for compounding pharmacies. Congress passed the DQSA in response to a 2012 fungal contamination outbreak linked to the New England Compounding Center (NECC) in Massachusetts, which caused 753 infections and 63 deaths — the largest drug safety crisis in US compounding history. The law drew a clearer line between pharmacies serving individual patients and facilities producing drugs at larger scale.

Feature	503A (Traditional pharmacy)	503B (Outsourcing facility)
Patient prescription required	Yes — patient-specific, every time	No — can produce batches without individual Rx
Production scale	Small batch, patient-specific	Large batch for multiple healthcare clients
Primary regulator	State board of pharmacy	FDA (direct registration and inspection)
FDA registration required	No	Yes
cGMP compliance required	No	Yes
Ships directly to patients	Yes	No
Sells to hospitals/clinics	No	Yes
USP quality standards	USP 795, USP 797, USP 800	USP standards + cGMP on top
Typical patient scenario	Telehealth Rx delivered to your home	Clinic administers compound during your visit

503A pharmacies are what most patients encounter. If your telehealth provider writes a prescription and a vial arrives at your home, it came from a 503A pharmacy. These pharmacies are regulated primarily by state boards of pharmacy — not the FDA directly. They must follow USP quality standards and source all bulk drug substances from FDA-registered manufacturers with a current certificate of analysis (COA). They do not need to register with the FDA or meet cGMP standards.

503B outsourcing facilities supply hospitals, clinics, and healthcare systems. They can produce larger batches without individual patient prescriptions. In exchange, they must register with the FDA, undergo FDA inspections, and comply with cGMP — the same manufacturing standards applied to pharmaceutical manufacturers. About 81 FDA-registered 503B facilities operate in the USA (Alvarez and Marsal, 2024), and approximately 20% also operate a connected 503A pharmacy.

One critical nuance: an FDA-inspected 503B facility is not the same as FDA-approved products. The facility’s processes are inspected — the finished compounded drugs themselves still do not go through NDA review.

What this means for you: if you receive a compounded peptide or hormone through a telehealth provider, the pharmacy is almost certainly operating under 503A. If you receive a compound administered at a clinic, it likely came from a 503B facility. Either way, the finished compound was not evaluated by the FDA for safety or efficacy. Quality depends entirely on the pharmacy’s sourcing, manufacturing practices, and quality controls.

Learn more about the DQSA and what it changed for compounding pharmacy oversight.

USP Quality Standards: What They Govern

The United States Pharmacopeia (USP) is an independent scientific organization that sets official quality standards for medicines, food ingredients, and dietary supplements in the USA. Three USP chapters govern compounding pharmacies directly.

USP 795 covers non-sterile compounding — capsules, creams, ointments, suppositories, and oral liquids. It governs ingredient quality, beyond-use dating (how long the preparation remains usable), environmental controls, and documentation requirements.

USP 797 covers sterile compounding — injectable preparations, eye drops, and inhalation solutions. USP 797 sets cleanroom environment standards, personnel training requirements, microbial contamination testing, and beyond-use dating for sterile compounds. This chapter directly governs the compounding of injectable peptides. A 503A pharmacy preparing injectable compounds must comply with USP 797.

USP 800 covers handling of hazardous drugs — medications that present risks due to their chemical properties. This chapter governs protective equipment, ventilation systems, and waste disposal for hazardous compounding.

503A pharmacies must comply with all three chapters. 503B outsourcing facilities must meet USP standards plus cGMP requirements on top — a higher standard that includes process validation, stability testing, and ongoing quality management systems.

The FDA enforces USP compliance at 503B facilities through its inspection program. At 503A pharmacies, enforcement falls to state pharmacy boards, which vary in inspection frequency and rigor across states.

Learn more about USP 797 requirements for sterile injectable compounding.

Who Uses Compounding Pharmacies?

Compounding addresses clinical situations where a commercially available drug does not meet a specific patient’s needs. The categories below represent the main clinical drivers.

Patient segment	Clinical driver	Compounding solution
Allergy / sensitivity	Dye, lactose, gluten, or preservative intolerance	Allergen-free custom formulation
Pediatric patients	Cannot swallow pills; need weight-appropriate dosing	Flavored liquid, lollipop, small-dose capsule
Geriatric patients (dysphagia)	Swallowing disorder	Transdermal gel, oral liquid, sublingual preparation
BHRT users	Need specific hormone dose/combination not commercially available	Custom cream, troche, capsule, pellet
Pain management	Multi-drug topical combinations	Custom compounded cream or gel
Dermatology patients	Non-standard concentrations; discontinued formulations	Customized strength topical
Veterinary patients	Species-specific dosing; palatability	Flavored transdermal, species-dosed liquid
Drug shortage patients	Commercially unavailable medication	Equivalent compounded formulation during FDA-declared shortage

Hormone replacement therapy is the most commonly compounded formulation category, accounting for approximately 36% of therapies dispensed by 503A pharmacies surveyed in 2025 (Alliance for Pharmacy Compounding). The median 503A compounding pharmacy dispenses approximately 350 compounded prescriptions per week, working with around 150 prescribers.

Drug shortages are a distinct legal trigger for compounding. Compounding pharmacies can legally prepare equivalent formulations of commercially unavailable drugs — but only when the FDA has officially declared a drug shortage. This is the pathway that allowed licensed pharmacies to compound semaglutide and tirzepatide during the GLP-1 shortage period in 2023–2024. As those shortages resolved, the FDA restricted compounding of these specific drugs. The shortage declaration — not general demand — is the legal trigger.

Can compounding pharmacies make peptides? This depends on the FDA’s bulk drug substance category lists. The FDA categorizes nominated bulk drug substances as Category 1 (under evaluation; compounding permitted) or Category 2 (significant safety concerns; compounding prohibited). A licensed pharmacy can only compound a peptide if its bulk drug substance appears on the Category 1 list.

In September 2023, the FDA moved 19 commonly used peptides — including BPC-157, TB-500, and Ipamorelin — to Category 2, blocking licensed compounding. As of March 2026, HHS Secretary RFK Jr. has signaled intent to reclassify approximately 14 of those 19 back to Category 1, but no formal FDA rulemaking has been published. See our FDA peptide reclassification guide for current status.

Learn more about which peptides are currently available through licensed compounding pharmacies.

Risks: What You Should Know

Key takeaways

• Compounded drugs have no FDA pre-market review of the finished product. Quality depends entirely on the pharmacy’s practices.
• Potency variation is documented. Studies of compounded thyroid and hormone preparations have found potency variation exceeding acceptable ranges in some samples.
• The 2012 NECC contamination outbreak — 753 fungal infections, 63 deaths — is the documented worst-case outcome and the event that triggered the modern regulatory framework.
• Cost is not consistently lower. A 2012 analysis found average ingredient costs for compounded drugs ($308.49) exceeded those for commercially available equivalents ($148.75). [Primary source flagged for editorial verification.]

Using a compounding pharmacy involves tradeoffs worth understanding before filling any compounded prescription.

No FDA pre-market review. The FDA does not evaluate a finished compounded drug for safety, effectiveness, or consistent potency before it reaches you. Quality depends on the pharmacy’s sourcing, equipment, and practices. This creates variability that does not exist with manufactured, FDA-approved drugs.

Potency and purity variation. Compounded drugs can differ from batch to batch in ways that manufactured drugs do not. Studies examining compounded thyroid and hormone preparations have found potency variation exceeding acceptable ranges in some samples. This risk is higher at pharmacies with weaker quality controls or inadequate equipment.

The NECC case: the documented worst-case outcome. In 2012, the New England Compounding Center in Massachusetts shipped contaminated methylprednisolone acetate — a steroid injection — to healthcare facilities across the USA. The contamination caused 753 fungal infections and 63 deaths. Patients received the compound through clinical settings without knowing the pharmacy’s quality practices. The outbreak directly triggered the DQSA of 2013 and the creation of the 503B regulatory framework.

Online pharmacy risks. The rise of telehealth and direct-to-consumer compounding has brought pharmacies that operate across state lines. Some ship internationally, do not verify prescriptions, or do not have a licensed pharmacist on staff. The FDA has issued warning letters to multiple online pharmacies for dosage errors in GLP-1 formulations, mislabeling, and sterility failures.

Cost. Compounded drugs are not consistently less expensive than manufactured equivalents. A 2012 analysis found that the average ingredient cost for compounded drugs was $308.49 compared to $148.75 for commercially available products [primary source flagged for editorial verification]. Exceptions exist — during the GLP-1 shortage period, compounded semaglutide and tirzepatide were significantly less expensive than brand-name alternatives. Insurance coverage is variable; many plans do not cover compounded drugs or cover them at a lower rate. Verify with your insurer before filling.

Learn more about how to evaluate the risk profile of any compounding pharmacy before filling a prescription.

How to Choose a Safe Compounding Pharmacy

Three tools exist for verifying a compounding pharmacy’s legitimacy: accreditation, licensing, and batch documentation.

Step 1 — Check PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) is a voluntary accreditation body that evaluates pharmacies against quality standards exceeding state minimum requirements. PCAB accreditation means the pharmacy has undergone a third-party quality audit covering sterile compounding practices, documentation, environmental testing, and personnel training. PCAB maintains a searchable database of accredited pharmacies at pcab.pharmacy.

Step 2 — Check NABP accreditation. The National Association of Boards of Pharmacy (NABP) offers the .pharmacy domain verification program and separate accreditation standards for compounding pharmacies. The NABP database allows you to verify whether a pharmacy is in good standing with state boards and has not received adverse regulatory action.

Step 3 — Verify the state pharmacy board license. Every 503A compounding pharmacy must hold a current license from the state board of pharmacy in the state where it operates. If the pharmacy ships across state lines — including to your state — it may need licenses in both states. Most state pharmacy board websites have public license verification tools.

Step 4 — Request a certificate of analysis (COA). A COA is a lab document that confirms the potency, purity, and sterility of a specific batch of a compounded drug. Every injectable compounded peptide or hormone should have a COA from an independent third-party laboratory. Ask for it before filling. A pharmacy that cannot provide a COA on request is a significant warning sign.

Warning: These signs indicate a pharmacy may not meet minimum quality standards:

• No COA available when requested for injectables
• No visible state pharmacy board license or accreditation
• Ships internationally without requiring a valid prescription
• No licensed pharmacist identified on staff or website
• Prices dramatically below comparable compounds from other sources
• No PCAB or NABP accreditation
• Makes therapeutic claims that go beyond what a licensed compounding pharmacy can legally represent

Learn more about how to verify a compounding pharmacy’s credentials before filling a prescription.

The Bottom Line

A compounding pharmacy is a legitimate, regulated part of the US healthcare system — but the absence of FDA review on finished compounded products means quality assurance depends on the pharmacy itself, and on you to choose carefully. The 503A and 503B frameworks provide structure, but enforcement varies significantly between state-regulated and FDA-inspected facilities. Before filling any compounded prescription, verify the pharmacy’s state license, check for PCAB or NABP accreditation, and request a COA for any injectable preparation. If a pharmacy cannot confirm its license or declines to provide COA documentation for injectables, that refusal is your answer.

Frequently Asked Questions

Does insurance cover compounded medications?

Coverage varies by plan and by the specific compound. Many insurers treat compounded drugs differently from manufactured equivalents — some cover certain formulations, others exclude them entirely. 503B-produced compounds administered in clinical settings may receive different treatment than 503A patient-specific compounds. Check with your insurer before filling any compounded prescription, and ask your prescriber whether a manufactured equivalent exists that your plan might cover instead.

What training do compounding pharmacists have?

All pharmacists receive foundational compounding training in pharmacy school. Many states require a demonstration of compounding competency before licensure. Pharmacists who specialize in sterile compounding can earn board certification as a BCSCP (Board-Certified Sterile Compounding Pharmacist) through the Board of Pharmacy Specialties. Training requirements for advanced compounding vary by state, and pharmacies may provide additional internal training beyond the minimum required.

Is a compounded drug the same as a generic drug?

No. A generic drug is FDA-approved and must demonstrate bioequivalence to its brand-name equivalent through the Abbreviated New Drug Application (ANDA) process. A compounded drug is prepared for an individual patient and has not been reviewed by the FDA for safety, effectiveness, or quality as a finished product. They serve different purposes — generics substitute for approved brand-name drugs; compounds fill clinical gaps those drugs cannot meet.

Can any pharmacy do compounding?

Over 32,000 of the approximately 56,000 US community pharmacies offer some compounding services. However, most handle only basic, non-sterile preparations. If you need a sterile injectable compound, a custom hormone formulation, or a complex multi-drug preparation, a specialist compounding pharmacy — particularly one with PCAB accreditation and USP 797 compliance for sterile preparations — is the appropriate choice. Not all pharmacies that offer compounding can handle injectables safely.

Are compounded peptides legal?

It depends on the specific peptide and its FDA classification. Compounding pharmacies can only prepare peptides whose bulk drug substances appear on the FDA’s Category 1 list (under evaluation; compounding permitted). In September 2023, the FDA moved 19 commonly used peptides — including BPC-157, TB-500, and Ipamorelin — to Category 2, blocking licensed compounding. As of March 2026, HHS has signaled potential reclassification for some of these, but no formal rule change has been published. See our FDA peptide reclassification tracker for current status.

How do I know if a compounding pharmacy is legitimate?

Verify three things: a current state pharmacy board license, PCAB or NABP accreditation, and the ability to provide a certificate of analysis for any injectable preparation. Legitimate pharmacies produce all three without hesitation. If a pharmacy cannot confirm its state license or declines to provide COA documentation for injectables, do not fill a prescription there.

Why are compounded drugs sometimes less expensive than brand-name medications?

Compounding pharmacies do not incur the research, clinical trial, and FDA approval costs that pharmaceutical manufacturers absorb. During FDA-declared drug shortage periods specifically — when compounding of a commercially unavailable drug is legally permitted — compounded alternatives can be substantially less expensive than branded equivalents. Outside shortage periods, compounded drugs are not consistently less expensive; ingredient costs can exceed those of commercially manufactured equivalents.

Considering peptide therapy through a licensed pharmacy? Consult a licensed physician to understand which compounds are currently available through Category 1 compounding and whether your health goals qualify for a physician-supervised protocol.

References

1. U.S. Food & Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
2. U.S. Food & Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
3. Alliance for Pharmacy Compounding (APC). 2025–2026 Snapshot of Pharmacy Compounding in America. University of Mary Washington Center for Business Research, 2025.
4. National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington, DC: National Academies Press, 2020. Appendix E: 503A and 503B Distribution Supplement. https://www.ncbi.nlm.nih.gov/books/NBK562889/
5. Drug Quality and Security Act (DQSA), Public Law 113-54. November 27, 2013. 21 U.S.C. §353a (503A), §353b (503B).
6. Alvarez and Marsal Life Sciences. Compounding Pharmacy Overview: Trends and Best Practices for Private Equity. 2025. https://www.alvarezandmarsal.com
7. TechTarget. Understanding the differences between 503A, 503B compounding pharmacies. https://www.techtarget.com/pharmalifesciences/feature/Understanding-the-differences-between-503A-503B-compounding-pharmacies
8. United States Pharmacopeia. USP 795 (Non-Sterile Compounding), USP 797 (Sterile Compounding), USP 800 (Hazardous Drugs). https://www.usp.org
9. U.S. Food & Drug Administration. New England Compounding Center (NECC) recall and investigation. https://www.fda.gov/drugs/drug-safety-and-availability/new-england-compounding-center-necc-recall-associated-fungal-meningitis
10. 2012 cost comparison ($308.49 vs. $148.75 average ingredient cost). [Primary source flagged for editorial verification — original citation pending confirmation.]

Disclaimer: PeptideRx provides physician-reviewed educational content about peptide therapy and related pharmaceutical topics. PeptideRx does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved as finished products. All information in this article reflects published regulatory guidance, organizational data, and cited sources. Consult a licensed healthcare provider before making any decisions about compounded medications or peptide therapy. Content medically reviewed [date]. Evidence grading criteria are working definitions pending formal review.